Top Markets
Coin of the day
Chimeric Therapeutics Limited Chimeric Therapeutics Limited

Chimeric Therapeutics Limited

CHM
Pozycja w akcjach #38385
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical... Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Cena akcji
$0.02468497
Kapitalizacja rynkowa
$1.01M
Zmiana (1 dzień)
-12.50%
Zmiana (1 rok)
-87.34%
Kraj
AU
Handel Chimeric Therapeutics Limited (CHM)

Kategoria

Wskaźnik P/B dla Chimeric Therapeutics Limited (CHM)
Wskaźnik P/B na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji Chimeric Therapeutics Limited, obecny wskaźnik P/B (TTM) wynosi 0. Na koniec 2026 wynosił 0.
Historia wskaźnika P/B dla Chimeric Therapeutics Limited od 2026 do 2026
Wskaźnik P/B na koniec każdego roku
Rok Wskaźnik P/B Zmień
Za mało danych dla podanych dat.
Wskaźnik P/B dla podobnych firm lub konkurentów
Firma Wskaźnik P/B Różnica wskaźnika P/B Kraj
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE